Advertisement
IHE vs XLV
Which ETF would AI Choose? iShares U.S. Pharmaceuticals ETF (IHE) vs. Health Care Select Sector SPDR Fund (XLV)
Key Takeaways
- IHE is a concentrated, pure-play bet on U.S. pharmaceutical manufacturers, while XLV spans the entire healthcare complex — pharmaceuticals, biotechnology, medical devices, insurers, and life sciences tools.
- Cost and scale heavily favor XLV, which carries a roughly 0.08% expense ratio versus about 0.37% for IHE.
- IHE is far more top-heavy, with its largest two names dominating the portfolio, amplifying single-stock and sub-sector risk relative to XLV.
- Both funds lean on Eli Lilly and Johnson & Johnson, but XLV spreads that exposure across many more diversified holdings.
- Tickeron AI Verdict: XLV — broader diversification, lower cost, and more balanced sector positioning give the Select Sector fund the structural edge for most investors.
Introduction
Healthcare is one of the most durable corners of the equity market, but "healthcare" is not a single trade. Investors comparing IHE and XLV are really weighing two different definitions of the sector. IHE isolates drugmakers, offering high-conviction exposure to pharmaceutical revenue, pipelines, and patent cycles. XLV, by contrast, captures the full healthcare value chain. These funds do not compete head-to-head as identical products; rather, they offer alternative exposures for similar goals. In the current environment of shifting regulatory scrutiny, drug-pricing debates, and obesity-drug momentum, understanding their structural differences matters more than chasing short-term price moves.
iShares U.S. Pharmaceuticals ETF (IHE) Overview
The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund that seeks to track the Dow Jones U.S. Select Pharmaceuticals Index. It provides concentrated exposure to U.S.-listed pharmaceutical companies, including vaccine producers and specialty drugmakers. The fund typically holds roughly 55 to 60 securities, though its weight is heavily concentrated at the top.
Top holdings include JNJ (Johnson & Johnson), LLY (Eli Lilly), MRK (Merck), PFE (Pfizer), VTRS (Viatris), RPRX (Royalty Pharma), BMY (Bristol-Myers Squibb), and ZTS (Zoetis). The two largest names, Johnson & Johnson and Eli Lilly, have each represented roughly 20% to 25% of assets in recent months, meaning the top ten holdings can account for about three-quarters of the fund. This concentration is a defining structural feature. With a net expense ratio of approximately 0.37%, IHE is meaningfully more expensive than broad sector funds, reflecting its niche mandate and smaller asset base.
Health Care Select Sector SPDR Fund (XLV) Overview
The Health Care Select Sector SPDR Fund (XLV), managed by State Street Global Advisors, seeks to track the Health Care Select Sector Index, which draws its constituents from the healthcare companies within the S&P 500. This is a passive, replication-based strategy that generally holds about 60 to 64 securities across the full healthcare spectrum.
Top holdings include LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), AMGN (Amgen), GILD (Gilead Sciences), ABT (Abbott Laboratories), and PFE (Pfizer). Its sub-sector allocation is broad: pharmaceuticals, health care equipment and supplies, providers and services, biotechnology, and life sciences tools. The top ten holdings account for roughly 60% of assets — still concentrated, but far less than IHE. At approximately 0.08%, XLV is among the least expensive healthcare ETFs available, with substantial liquidity and scale.
Industry and Thematic Backdrop
Both funds operate within a sector shaped by several overlapping forces. Demand for GLP-1 (glucagon-like peptide-1) obesity and diabetes treatments has driven investor attention toward large-cap drugmakers, particularly Eli Lilly. At the same time, drug-pricing legislation and regulatory scrutiny in Washington create persistent headline risk for pure pharmaceutical exposure. Macro conditions also matter: healthcare is often viewed as a defensive, lower-beta allocation that can hold up better when economic growth slows. Interest-rate expectations influence valuations of long-duration growth names in biotech and medical technology, while merger activity and patent cliffs periodically reshape the pharmaceutical landscape. These dynamics affect both funds, but they land with very different intensity on a concentrated pharma-only vehicle versus a diversified sector fund.
Performance and Positioning Comparison
Over recent weeks and months, the two funds have diverged in ways that reflect their structure. IHE has been more volatile and more sensitive to the fortunes of its largest drugmakers, with Eli Lilly and Johnson & Johnson acting as dominant performance drivers. When pharma-specific momentum — such as obesity-drug enthusiasm — accelerates, IHE can capture more of that upside. However, that same concentration magnifies drawdowns when sentiment cools or regulatory headlines turn negative. XLV, by comparison, has shown more measured relative positioning, buffered by exposure to insurers, device makers, and life sciences tools that do not move in lockstep with drug pricing. This broader mix generally produces lower relative volatility and steadier sector participation, though it can lag during sharp pharma-led rallies. For investors weighing relative positioning, XLV offers smoother exposure; IHE offers a higher-beta, thematic tilt.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of securities using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending names, and breakout candidates far more efficiently than manual screening, turning raw market data into actionable watchlists. Whether you are comparing ETFs or hunting for the next momentum leader, the AI Screener brings structure to the process. Explore the AI Screener to refine your own market research today.
Tickeron AI Verdict
Based on observable structural factors, Tickeron's AI would likely favor XLV for most investor profiles. The fund's broader diversification, materially lower expense ratio, superior liquidity, and balanced sub-sector exposure provide a more resilient framework across market cycles. While IHE may outperform during concentrated pharmaceutical rallies, its top-heavy structure and higher cost introduce concentration and single-stock risk that the AI framework typically penalizes. XLV captures sector-wide trends — including pharma momentum — without overcommitting to any single theme, giving it a more consistent risk-adjusted profile. Accordingly, XLV emerges as the more probable structural winner of this comparison.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IHE is a StrongBuy and XLV is a Hold.
IHE in upward trend: price rose above 50-day moving average on October 20, 2026
IHE moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on IHE as a result. In 71 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for IHE just turned positive on October 15, 2026. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
The 10-day moving average for IHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 285 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 246 of 288 cases where IHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for IHE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 28 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 70 cases where IHE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
IHE broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
XLV in downward trend: price may decline as a result of having broken its higher Bollinger Band on November 04, 2026
XLV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 29 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 67 cases where XLV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on XLV as a result. In 77 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on October 09, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
XLV moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +2.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 263 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 230 of 271 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
| IHE | XLV | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 78% | 4 days ago 78% |
| Stochastic ODDS (%) | 4 days ago 76% | 4 days ago 76% |
| Momentum ODDS (%) | 4 days ago 84% | 4 days ago 80% |
| MACD ODDS (%) | 4 days ago 88% | 4 days ago 81% |
| TrendWeek ODDS (%) | 4 days ago 78% | 4 days ago 78% |
| TrendMonth ODDS (%) | 4 days ago 85% | 4 days ago 84% |
| Advances ODDS (%) | 11 days ago 83% | 11 days ago 81% |
| Declines ODDS (%) | 7 days ago 78% | 4 days ago 81% |
| BollingerBands ODDS (%) | 4 days ago 86% | 4 days ago 88% |
| Aroon ODDS (%) | 4 days ago 85% | 4 days ago 85% |
Advertisement
IHE and
Correlation & Price change
A.I.dvisor indicates that over the last year, IHE has been closely correlated with LLY. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if IHE jumps, then LLY could also see price increases.
XLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FMED | 31.64 | 0.65 | +2.09% |
| Fidelity Disruptive Medicine ETF (FMED) | |||
| WTID | 2.80 | 0.03 | +0.90% |
| MicroSectors Energy 3X Inverse Leveraged ETNs (WTID) | |||
| FPE | 17.09 | 0.07 | +0.41% |
| First Trust Preferred Securities & Income ETF (FPE) | |||
| SCIO | 20.26 | 0.02 | +0.12% |
| First Trust Structured Credit Income Opportunities ETF (SCIO) | |||
| CGHY | 24.61 | N/A | N/A |
| Capital Group High Yield Bond ETF | |||